BRAF and neoplasm: On the other hand, PFS benefit of immunotherapy was nearly identical for patients with BRAF wild-type tumours and those with BRAF V600E tumours, although arguably, the control arm regimens were inadequate for this subpopulation and a triplet chemotherapy with bevacizumab should be more effective (24).